Multi-center, Prospective, Cohort Study to Evaluate the Relationship of Stroke Recurrence and Anti-platelet Resistance in Ischemic Stroke Patients
Completed
- Conditions
- Ischemic Stroke
- Registration Number
- NCT03823274
- Lead Sponsor
- Yuhan Corporation
- Brief Summary
This cohort study will evaluate the relatiobship of stroke recurrence and anti-platelet resistance in ischemic stroke patients
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1011
Inclusion Criteria
- Men and women over 60 years old at the time of written consent
- Those admitted to the hospital within 72 hours after acute cerebral infarction and treated with Aspirin 100 mg and Clopidogrel 75 mg
- Written informed consent voluntarily signed
Exclusion Criteria
- Those with evidence other brain lesions such as brain tumors
- Those who need oral anticoagulants other than vitamin K antagonists or anticoagulant therapy of warfarin
- Contraindicate to Aspirin or Clopidogrel or allergic to the drug
- Subjects who are at risk of active pathological bleeding such as digestive ulcer and intracranial hemorrhage
- Cancer disease that can shorten life expectancy
- Patient's condition that may interfere with participation in study such as mental illness, mental retardation, dementia, drug abuse, and alcoholism
- Subjects other than the above unsuitable for this clinical study identified by Investigator
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method evaluate the relationship of stroke recurrence and anti-platelet resitance 12weeks To evaluate the relationship of stroke recurrence and anti-platelet resitance in ischemic stroke patients receiving aspirin 10mmg and clopidogrel 75mg for 12weeks
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Chungnam National University Hospital
🇰🇷Daejeon, Korea, Republic of